NCT00349596View on ClinicalTrials.gov

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Acute Lymphocytic Leukemia
Interventions
DRUG

Decitabine

Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00349596 - A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | Biotech Hunter | Biotech Hunter